Journal profile · Pharmacology & Pharmacy
Pharmaceutical Development and Technology
ISSN 1083-7450 · eISSN 1097-9867 · Informa Healthcare · UNITED STATES · Bimonthly · Founded 1996
Pharmaceutical Development and Technology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.09; subscription journal; median 115 days to acceptance (98 articles, last 24 months); community-reported acceptance: easy; 109 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Pharmaceutical Development and Technology is published by Informa Healthcare and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Drug Solubulity and Delivery Systems, Advanced Drug Delivery Systems and Advancements in Transdermal Drug Delivery, together about 49.6% of its articles. Its main subfields are Pharmaceutical Science. (generated from OpenAlex topic counts and CAS ranking data)
Pharmaceutical Development & Technology publishes research on the design, development, manufacture, and evaluation of conventional and novel drug delivery systems, emphasizing practical solutions and applications to theoretical and research-based problems. The journal aims to publish significant, innovative and original research to advance the frontiers of pharmaceutical development and technology. Through original articles, reviews (where prior discussion with the EIC is encouraged), short reports, book reviews and technical notes, Pharmaceutical Development & Technology covers aspects such as: -Preformulation and pharmaceutical formulation studies -Pharmaceutical materials selection and characterization -Pharmaceutical process development, engineering, scale-up and industrialisation, and process validation -QbD in the form a risk assessment and DoE driven approaches -Design of dosage forms and drug delivery systems -Emerging pharmaceutical formulation and drug delivery technologies with a focus on personalised therapies -Drug delivery systems research and quality improvement -Pharmaceutical regulatory affairs This journal will not consider for publication manuscripts focusing purely on clinical evaluations, botanicals, or animal models.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics22.2%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics17.1%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics10.3%
- Analytical Methods in PharmaceuticalsChemistry5.5%
- Protein purification and stabilityBiochemistry, Genetics and Molecular Biology4.8%
- Crystallization and Solubility StudiesMaterials Science4.6%
- Nanoparticle-Based Drug DeliveryMaterials Science4.3%
- Microencapsulation and Drying ProcessesAgricultural and Biological Sciences3.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.09LetPub ·
- CiteScore 2026-06
- 4.7LetPub ·
- SJR 2026-06
- 0.47LetPub ·
- SNIP 2026-06
- 0.54LetPub ·
- h-index
- 50LetPub ·
- h-index
- 85OpenAlex ·
- i10-index
- 1,617OpenAlex ·
- 2-year mean citedness
- 2.89OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 3.42%LetPub ·
Volume
- Articles per year
- 108LetPub ·
Articles by year OpenAlex count · 2,805 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 70 | 11 | 17 |
| 2025 | 109 | 13 | 274 |
| 2024 | 107 | 17 | 535 |
| 2023 | 85 | 13 | 745 |
| 2022 | 91 | 17 | 1,010 |
| 2021 | 88 | 18 | 1,363 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
115 daysMedian, submission to acceptance · P25–P75 82 days – 163 days
- Acceptance to online
- median 11 days (98 articles)
- Submission to online
- median 125 days
- Sample
- 98 articles with submission and acceptance dates (205 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Informa Healthcare
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1996
- ISSN
- 1083-7450
- Electronic ISSN
- 1097-9867
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Pharmaceutical Development and Technology
What CAS zone is Pharmaceutical Development and Technology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Pharmaceutical Development and Technology is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Pharmaceutical Development and Technology?
The latest impact factor listed by LetPub is 3.09; CiteScore 4.7, h-index 85.
How long does peer review take at Pharmaceutical Development and Technology?
Based on the dates recorded on 98 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 115 days (interquartile range 82–163 days); authors report an average review time of about 1 month; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Pharmaceutical Development and Technology?
According to LetPub and DOAJ records, Pharmaceutical Development and Technology is indexed in SCIE and Scopus.
Is Pharmaceutical Development and Technology open access, and what is the APC?
Pharmaceutical Development and Technology is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .